相关实验视频
Updated: Jan 11, 2026

A Spheroid Killing Assay by CAR T Cells
Published on: December 12, 2018
在固体瘤中对CAR-T细胞输送和疗效的生理学基础的药理动力学模型
Andreas G Hadjigeorgiou1, Lance L Munn2, Triantafyllos Stylianopoulos1
1Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia 2109, Cyprus.
血管正常化通过重编程瘤微环境来提高CAR-T细胞治疗在固体瘤中的疗效. 这一策略改善了T细胞的透,并降低了所需的CAR-T细胞剂量,优化了癌症治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理动力学 药理动力学
背景情况:
- 异常的瘤血管阻碍了T细胞在瘤微环境 (TME) 中的有效性.
- 抗VEGF疗法诱导的血管正常化先前在质母细胞瘤小鼠模型中改善了CAR-T细胞治疗.
研究的目的:
- 开发一个模拟CAR-T细胞和内源性免疫细胞动态后血管正常化的药理动力学模型.
- 使用计算建模,优化对实体瘤的CAR-T细胞治疗策略.
主要方法:
- 基于生理学的药物动力学建模.
- 在TME中模拟CAR-T细胞和免疫细胞相互作用.
- 对TME组成和CAR-T细胞功能的血管正常化影响的分析.
主要成果:
- 血管正常化将TME从免疫抑制转变为免疫支持,增强CD8+T细胞和CAR-T细胞的透.
- 模型预测瘤控制所需的CAR-T细胞剂量减少了五倍.
- 优化的CAR-T细胞输液时间和组合疗法 (例如,带有树突正常化) 显示出更好的疗效.
- 当地的CAR-T细胞递送增强了TME度和免疫细胞招募.
结论:
- 血管正常化是改善固体瘤CAR-T细胞治疗的关键策略.
- 药物动力学建模为优化CAR-T细胞剂量,测序和输送提供了一个框架.
- 向瘤血管和肌瘤对治疗具有挑战性的脱质性瘤具有前景.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model Approaches for Pharmacokinetic Data: Physiological Models
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Physiological Pharmacokinetic Models: Assumption with Protein Binding

